Julie Vose, M.D., M.B.A.
Professor, Internal Medicine
Division of Oncology & Hematology
UNMC Oncology/Hematology Division
987680 Nebraska Medical Center
Omaha, NE 681980-7680
Main practice location:
Peggy D. Cowdery Patient Care Center
Lied Transplant Center
987835 Nebraska Medical Center
Omaha, NE 68198-7835
Cancer Center at Village Pointe
111 North 175th Street
Omaha, NE 68118
University of Colorado, M.B.A. (2011)
University of Nebraska Medical Center, Resident, (1987)
University of Nebraska Medical Center, Chief Resident, (1988)
University of Nebraska Medical Center, Fellow, (1990)
South Dakota State University, BS, (1978)
University of Nebraska Medical Center, B.S. MT (ASCP), (1979)
University of Nebraska Medical Center, M.D., (1984)
The Nebraska Medical Center University Hospital
Research in novel therapies for Hodgkin’s disease, non-Hodgkin’s lymphoma, Multiple Myeloma, CLL
Dr Vose is the Neumann M. and Mildred E. Harris Professorial Chair and is the current Chief of the Oncology/Hematology Division in the Department of Internal Medicine at UNMC. Dr Vose received all of her medical education and training at UNMC and has been on faculty since 1990. Dr Vose is an internationally known leading expert in the treatment of patients with lymphoma. Dr Vose has served in many national and international review panels and is actively involved in various administrative positions in various local and national organizations. Dr Vose is actively involved in various novel clinical trials and is a member of the Nebraska Lymphoma Study Group. Dr Vose is the current co-program leader of the Hematologic Malignancy Program at the UNMC Eppley Cancer Center. Dr Vose has published over 300 articles in various medical journals, most of which deals with finding optimum care and treatment for patients with lymphoma. She has served on the editorial boards of various hematology and oncology journals, and serves as an expert reviewer as well.
Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, Rudiger T, Pileri S, Nakamura S, Nathwani B, Campo E, Berger F, Coiffier B, Kim WS, Hote H, Federico M, Au WY, Tobinai K, Armitage JO, Vose JM, Peripheral T-cell lymphoma, not otherwise specified: A report of 340 cases from the International Peripheral T-cell Lymphoma Project, Blood 117(12), 3402 – 3408, March 2011.
Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D, Rich L, Blumel S, Proia NK, Liesveld J, Fisher RI, Armitage JO, Grant S, Leonard JP, The combination of bendamustine, bortezomib and rituximab for patients with relapsed/refractory indolent and mangle cell non-Hodgkin lymphoma, Blood 117(10), 2807 – 2812, March, 2011.
Witzig TE, Vose JM, Zinzani L, Reeder CB, Buckstein R, Polikoff JA, Bouabdallah R, Haioun C, Tilly H, Guo P, Pietronigro D, Ervin-Haynes AL, Czuczman MS, An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma, Ann Onc, e-pub Jan. 12, 2011.
Flowers CR, Sinha R, Vose JM, Improving outcomes for patients with diffuse large B-cell lymphoma, CA Cancer J Clin 60(6), 303-408, Nov-Dec, 2010.
Younes A, Vose JM, Zelenetz AD, Smith MR, Burris HA, Ansell SM, Klein J, Halpern W, Miceli R, Kumm E, Fox NL, Czuczman MS, A phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin’s lymphoma; Br Journal of Cancer 103, 1783-1787, Nov, 2010.
Vose, JM, Weisenburger DD, Loberiza FR, Arevalo A, Bast M, Armitage J, Bierman PJ, Bociek RG, Armitage JO, Late relapse in patients with diffuse large B-cell lymphoma, Br J Haematol 151(4), 354-358, Nov., 2010.
Tomblyn MR, Ewell M, Bredeson C, Kahl BS, Goodman SA, Horowitz MM, Vose JM, negrin RS, Laport GG, Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response, Biol Blood Marrow Transplant 10, (e-published), Nov, 2010.
Vose JM, Understanding evaluation and management of primary cutaneous and systemic ALCL, Oncology 24(7), 594, June, 2010.
Juweid ME, Vose JM, Imaging in early stage Hodgkin’s lymphoma, N Engl J Med 362;10, 962, March, 2010.
O’Connor OA, Portlock C, Moskowitz C, Hamlin P, Straus D, Gerecitano J, Gonen M, Dumitrescu O, Sarasohn D, Butos J, Neylon E, Cortelli BM, Blumel S, Evens AM, Zelenetz AD, Wright J, Cooper B, Winter J, Vose JM, Time to treatment response in patients with follicular lymphoma treated with Bortezomib is longer compared with other histologic subtypes, Clin Cancer Res 16(2), 719-726, Jan, 2010.
Fenske, TS, Hari PN, Carreras J, Zhang J, Kamble RT, Bolwell BJ, Cairo MS, Champlin RE, Chen YB, Freytes CO, Gale RP, Hale GA, Ilhan O, Khoury HJ, Lister J, Maharaj D, Marks DI, Munker R, Pecora AL, Rowlings PA, Shea TC, Stiff P, Wiernik PH, Winter JN, Rizzo JD, van Besien K, Lazarus HM, Vose JM, Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma, Biol Blood Marrow Transplant 15 1455-1464, Nov, 2009.
Vose JM, Ho Ad, Coiffier B, Corradini P, Khouri I, Sureda A, van Besien K, Dipersio J, Advances in mobilization for the optimization of autologous stem cell transplantation, Leuk and Lymphoma 50(9), 1412-1421, Sept, 2009.
Fu K, Weisenburger DD, Choi WL, Perry KD, Smith LM, Shi X, Hans CP, Greiner TC, Bierman PJ, Bociek RG, Armitage JO, Chan WC, Vose JM, Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma, J Clin Oncol, 26, 28, 4587-4594, Oct 1, 2008.
Vose JM, Peripheral T-cell non-Hodgkin’s Lymphoma, Hematol Oncol Clin N Am, 22, 997-1005, Oct., 2008.
Vose JM, Armitage JO, et al., International T-cell Lymphoma Project, International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes, J Clin Oncol 26, 25, 4124-4130, Sept, 2008.